News for Healthier Living

A New Treatment for Head and Neck Cancer

On Nov. 5, the U.S. Food and Drug Administration (FDA) approved the use of a new drug to treat head and neck cancer, the first in seven years. Called amivantamab, the drug is the first to target two growth receptors for head and neck cancer simultaneously, reducing the cancer's ability to adapt to the treatment. The FDA granted amivantamab accelerated approval because of the promising results it showed during clinical trials, which were led by Yale School of Medicine researchers.

November 20, 2026


November 20 2026

November 19 2026

November 18 2026

November 17 2026

November 16 2026

November 15 2026

November 13 2026

November 12 2026

November 11 2026

November 10 2026

November 9 2026

November 8 2026

November 7 2026